Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.91 |
| ▸ | RXRA | P19793 | 2/20 | 0.70 |
| ▸ | RXRB | P28702 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ERN1 | O75460 | 1/20 | 0.59 |
| ▸ | CD74 | P04233 | 1/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30436085 | 0.98 | KMO (0.95) | KMORXRARXRBLMNAGAA | |
| SCHEMBL250880 | 0.98 | KMO (0.95) | KMORXRARXRBLMNAGAA | |
| SCHEMBL14683877 | 0.98 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL29577419 | 0.98 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL31752544 | 0.98 | KMO (0.95) | KMORXRARXRBLMNAGAA | |
| SCHEMBL71238 | 0.97 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL30725957 | 0.97 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL29904709 | 0.97 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL849169 | 0.95 | KMO (1.00) | KMORXRARXRBLMNAGAA | |
| Water SCHEMBL4183567 | 0.95 | KMO (0.83) | KMORXRARXRBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103249735-B | Tricyclic compounds and methods of making and using the same | ZAFGEN CORP. (US) | 2016-04-06 | — | — | CN | claimed |
| CN-103249735-A | Tricyclic compounds and methods of making and using the same | ZAFGEN CORP | 2013-08-14 | — | — | CN | claimed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012012642-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-01-26 | — | — | WO | claimed |
| CN-101228146-A | Benzofuran derivatives with therapeutic activities | PHARMOS CORP (US) | 2008-07-23 | — | — | CN | claimed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250000993-A1 | ANTI-HUMAN CD33 BET DEGRADER ANTIBODY-DRUG CONJUGATES | ABBVIE INC. | 2025-01-02 | — | — | US | disclosed |
| CN-108440528-A | Fourth Ring Bu Luomo structural domain inhibitor | 艾伯维公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-105026403-B | Tetracyclic Bromodomain Inhibitors | 艾伯维公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-103249735-B | Tricyclic compounds and methods of making and using the same | ZAFGEN CORP. (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-103249735-A | Tricyclic compounds and methods of making and using the same | ZAFGEN CORP | 2013-08-14 | — | — | CN | disclosed |
| EP-2595988-A1 | TRICYCLIC COMPOUNDS AND METHDS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| CN-1732154-B | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA | 2010-09-08 | — | — | CN | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| CN-101228146-A | Benzofuran derivatives with therapeutic activities | PHARMOS CORP (US) | 2008-07-23 | — | — | CN | disclosed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| CN-1732154-A | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000993-A1 | ANTI-HUMAN CD33 BET DEGRADER ANTIBODY-DRUG CONJUGATES | BET1, BRD3, CHD3 | KMO 2073/4885RXRA 1637/4885RXRB 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.